Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis.

Bibliographic Details
Main Authors: Xiaoyun Hu, Rong Li, Qi Li, Mengya Zang, Guosheng Yuan, Jinzhang Chen
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Infectious Diseases
Subjects:
Hepatocellular carcinoma (HCC)
Hepatitis B virus (HBV)
Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
Reactivation
Tenofovir alafenamide fumarate (TAF)
Online Access:https://doi.org/10.1186/s12879-022-07602-0

Internet

https://doi.org/10.1186/s12879-022-07602-0

Similar Items